Vitamin B12 Scientific References and Clinical Studies

1. Vitamin B12 Scientific References and Vitamin B12 Clinical Studies: How This Library Is Organized

Vitamin B12 (cobalamin) is an essential nutrient needed for red blood cell formation, nervous system function and DNA synthesis. It is also one of the most frequently supplemented vitamins, and claims about it range from well-established to speculative. This library helps you see which is which. It lists key Vitamin B12 scientific references and Vitamin B12 clinical studies, grouped by the type of evidence, with a plain-language note on what each source can and cannot tell us.

Why this matters: a randomized trial, a population association and a cell experiment answer different questions. Treating them as equivalent is a common source of misinformation. By grouping studies by design, you can judge how much weight each deserves, whether you are a student, clinician, researcher or an informed reader.

Selection criteria

• Source quality: peer-reviewed articles in recognized journals, plus official health-authority documents (for example, the U.S. National Institutes of Health Office of Dietary Supplements and the European Food Safety Authority).
• Relevance: studies that address B12 deficiency, absorption, treatment routes, supplementation outcomes, safety, drug-related changes in B12 status, and biological mechanisms.
• Date range: publications from 1966 to 2021 are included in this edition, favoring landmark and widely cited work. This is a curated selection and not an exhaustive systematic search. Newer literature should be searched in PubMed before relying on this list as current.
• Exclusions: unreviewed commercial material, marketing content and sources whose details could not be confirmed.

How to read the entries

Each entry notes year, design, population and dose where these are reliably known. Where a detail (for example, exact sample size or funding) could not be confirmed, the table says "verify in source" rather than guessing. Funding sources and conflicts of interest were not systematically extracted in this edition and must be checked in each paper before they are reported.

Evidence hierarchy used here

This is an explanatory ordering, not a formal grading system such as GRADE: systematic reviews and meta-analyses of randomized trials, then individual randomized trials, then observational studies, then pharmacokinetic and mechanistic human work, then preclinical (animal and cell) research. Higher in the list generally means stronger evidence for clinical questions, but quality varies within every category.

2. Systematic Reviews and Meta-Analyses

These pool or appraise multiple studies. They are strongest when their underlying studies are strong and consistent.

Vidal-Alaball J, Butler CC, Cannings-John R, et al. (2005). Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews, (3):CD004655. doi:10.1002/14651858.CD004655.pub2 A Cochrane review of randomized trials comparing oral and intramuscular routes. It found that high-dose oral B12 appeared comparable to injection for achieving adequate serum levels in people with deficiency. Limitations: few and small trials, short follow-up, and limited data on neurological outcomes.

Wang H, Li L, Qin LL, et al. (2018). Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database of Systematic Reviews, 3:CD004655. doi:10.1002/14651858.CD004655.pub3 An update of the review above. It also found evidence that oral high-dose treatment can normalize serum B12 comparably to injection in the studied groups, with low certainty regarding clinical outcomes.

Clarke R, Halsey J, Lewington S, et al.; B-Vitamin Treatment Trialists' Collaboration. (2010). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of Internal Medicine, 170(18):1622-1631. doi:10.1001/archinternmed.2010.348 B-vitamin regimens (including B12 in many trials) lowered homocysteine but did not significantly reduce vascular events, cancer or mortality overall. Limitation: the regimens were combinations, so effects of B12 alone cannot be isolated.

Niafar M, Hai F, Porhomayon J, Nader ND. (2015). The role of metformin on vitamin B12 deficiency: a meta-analysis review. Internal and Emergency Medicine, 10(1):93-102. doi:10.1007/s11739-014-1154-0 (verify DOI before publication) A meta-analysis reporting lower B12 levels in metformin users than in comparison groups. Limitation: heterogeneity across included studies and variable assays.

Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. (2013). How prevalent is vitamin B12 deficiency among vegetarians? Nutrition Reviews, 71(2):110-117. doi:10.1111/nure.12001 A systematic review of B12 status in vegetarians, reporting a high prevalence of low status in some populations and wide variation by region, age and diet type. Limitation: differing definitions of deficiency across studies.

Infante M, Leoni M, Caprio M, Fabbri A. (2021). Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World Journal of Diabetes, 12(7):916-931. doi:10.4239/wjd.v12.i7.916 A narrative review of the metformin-B12 literature, useful as an overview; it is not a quantitative synthesis.

3. Randomized Controlled Trials

RCTs can show whether an intervention causes an outcome, but individual trials may be small, short or limited to specific populations.

Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. (1998). Effective treatment of cobalamin deficiency with oral cobalamin. Blood, 92(4):1191-1198. A small randomized trial comparing oral cobalamin (high dose) with intramuscular cobalamin in people with deficiency; oral treatment achieved comparable hematological and biochemical responses over the study period. Limitations: small sample, short follow-up. (Verify exact dose and sample size in source.)

Eussen SJPM, de Groot LCPGM, Clarke R, et al. (2005). Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Archives of Internal Medicine, 165(10):1167-1172. doi:10.1001/archinternmed.2005.1167 (verify DOI before publication) A dose-finding trial in older adults with mild deficiency using several oral cyanocobalamin doses over about 12 weeks, showing a dose-response in biochemical markers. Limitation: biochemical rather than clinical endpoints and short duration.

de Jager J, Kooy A, Lehert P, et al. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 340:c2181. doi:10.1136/bmj.c2181 A randomized, placebo-controlled trial in patients with type 2 diabetes treated with insulin who also received metformin or placebo for several years. Metformin was associated with lower B12 levels and higher deficiency risk. Limitation: population was insulin-treated diabetes; findings may not apply to everyone on metformin.

Smith AD, Smith SM, de Jager CA, et al. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial (VITACOG). PLoS ONE, 5(9):e12244. doi:10.1371/journal.pone.0012244 Older adults with mild cognitive impairment received a folic acid, B12 and B6 combination or placebo for 2 years. Brain atrophy rates were slower with treatment, especially in people with elevated baseline homocysteine. Limitation: combination intervention; surrogate imaging outcome; effects on clinical dementia not shown.

Lonn E, Yusuf S, Arnold MJ, et al.; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine, 354(15):1567-1577. doi:10.1056/NEJMoa060900 A large trial (over 5,000 participants with vascular disease or diabetes) of a folic acid, B6 and B12 combination. It did not reduce the main composite cardiovascular outcome. Limitation: combination treatment in a population with generally adequate B12 status.

Dangour AD, Allen E, Clarke R, et al. (2015). Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial. American Journal of Clinical Nutrition, 102(3):639-647. doi:10.3945/ajcn.115.110775 (verify details before publication) A trial of oral B12 supplementation in older adults with low B12 status that did not show clear cognitive or neurological benefit over the study period. Limitation: limited duration and population specificity.

4. Observational Human Studies

Observational studies show associations. They cannot prove causation because of confounding.

Lam JR, Schneider JL, Zhao W, Corley DA. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22):2435-2442. doi:10.1001/jama.2013.280490 A large case-control study in a U.S. integrated health system. Longer and higher-dose acid-suppressant use was associated with higher odds of a B12 deficiency diagnosis. Limitation: observational design, possible residual confounding.

Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism, 101(4):1754-1761. doi:10.1210/jc.2015-3754 Follow-up analysis from a large cohort originally randomized to metformin or placebo: longer metformin exposure was associated with a higher risk of low B12 levels. Limitation: B12 was measured at selected times and the analysis was secondary to the main trial.

Tucker KL, Rich S, Rosenberg I, et al. (2000). Plasma vitamin B-12 concentrations relate to intake source in the Framingham Offspring Study. American Journal of Clinical Nutrition, 71(2):514-522. Plasma B12 was more strongly associated with intake from fortified cereal or supplements than with intake from meat or dairy, consistent with differences in absorption of food-bound versus free B12. Limitation: cross-sectional design in one cohort.

Morris MS, Jacques PF, Rosenberg IH, Selhub J. (2007). Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. American Journal of Clinical Nutrition, 85(1):193-200. doi:10.1093/ajcn/85.1.193 An analysis of U.S. national survey data suggesting that the effects of high folate and low B12 status on anemia and cognition interact. Limitation: cross-sectional design.

Arendt JFH, Pedersen L, Nexo E, Sørensen HT. (2013). Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study. Journal of the National Cancer Institute, 105(23):1799-1805. doi:10.1093/jnci/djt315 High plasma B12 was associated with a subsequent cancer diagnosis, particularly in the first year. The authors interpret this as a marker of existing disease, not evidence that B12 causes cancer. Limitation: observational; does not address supplementation.

5. Pharmacokinetic Studies

These describe how B12 is absorbed, distributed and cleared.

Heyssel RM, Bozian RC, Darby WJ, Bell MC. (1966). Vitamin B12 turnover in man: the assimilation of vitamin B12 from natural foodstuff by man and estimates of minimal daily dietary requirements. American Journal of Clinical Nutrition, 18(3):176-184. A classic study that quantified absorption and turnover, showing that intrinsic factor-mediated absorption saturates at small doses. Limitation: small cohorts and older methods.

Berlin H, Berlin R, Brante G. (1968). Oral treatment of pernicious anaemia with high doses of vitamin B12 without intrinsic factor. Acta Medica Scandinavica, 184(4):247-258. Early evidence that high oral doses can work without intrinsic factor, consistent with a small passive-diffusion pathway that is the rationale for high-dose oral therapy. Limitation: small study with older assay methods.

Official dietary reference documents: The European Food Safety Authority (2015), Scientific Opinion on Dietary Reference Values for cobalamin (vitamin B12), EFSA Journal, 13(7):4150, doi:10.2903/j.efsa.2015.4150; and the U.S. National Institutes of Health Office of Dietary Supplements, Vitamin B12 Fact Sheet for Health Professionals (https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/), summarize absorption data and intake recommendations.

6. Safety and Toxicology Evidence

B12 is generally regarded as having low toxicity at usual intakes. The Institute of Medicine (1998) did not set a tolerable upper intake level for B12 because of insufficient evidence of adverse effects, and the EFSA (2015) opinion likewise reported no upper level. Absence of an upper level does not mean no risk in every individual, and monitoring is appropriate in medical contexts.

• Institute of Medicine. (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academies Press. Foundational U.S. reference.
• Arendt 2013 (above) is often discussed in safety conversations but concerns elevated levels as a disease marker, not toxicity from supplements.
• Kang D, Shi B, Erfe MC, Craft N, Li H. (2015). Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. Science Translational Medicine, 7(293):293ra103. doi:10.1126/scitranslmed.aab2009. A small human and laboratory study suggesting B12 can alter skin bacterial gene expression and may be linked to acne flares in some people. Limitations: small sample, preliminary evidence; it does not establish a general safety problem.
• Nitrous oxide: Sanders RD, Weimann J, Maze M. (2008). Anesthesiology, 109(4):707-722. doi:10.1097/ALN.0b013e3181870a17. Describes how nitrous oxide inactivates cobalamin and can contribute to neurological injury (see Section 7).

7. Mechanistic Studies

These explain how B12 functions, supporting biological plausibility but not proving clinical benefit.

Nielsen MJ, Rasmussen MR, Andersen CBF, Nexø E, Moestrup SK. (2012). Vitamin B12 transport from food to the body's cells: a sophisticated, multistep pathway. Nature Reviews Gastroenterology & Hepatology, 9(6):345-354. doi:10.1038/nrgastro.2012.76 A review of the pathway from food release through intrinsic factor binding to cellular uptake. Useful for understanding why acid suppression, ileal disease and certain drugs may alter absorption.

Banerjee R, Ragsdale SW. (2003). The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes. Annual Review of Biochemistry, 72:209-247. doi:10.1146/annurev.biochem.72.121801.161828 Describes the enzymes that use cobalamin, including methionine synthase and methylmalonyl-CoA mutase, which underlie the biomarkers homocysteine and methylmalonic acid.

Green R, Allen LH, Bjørke-Monsen AL, et al. (2017). Vitamin B12 deficiency. Nature Reviews Disease Primers, 3:17040. doi:10.1038/nrdp.2017.40 A comprehensive review of causes, diagnosis and management.

Stabler SP. (2013). Vitamin B12 deficiency. New England Journal of Medicine, 368(2):149-160. doi:10.1056/NEJMcp1113996 A clinical review that is widely cited for diagnosis and biomarker interpretation.

Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. (2014). Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology, 166(4):496-513. doi:10.1111/bjh.12959 A guideline that is useful for clinical context.

Carmel R. (2008). How I treat cobalamin (vitamin B12) deficiency. Blood, 112(6):2214-2221. doi:10.1182/blood-2008-03-040253 Expert review of diagnosis and treatment.

Hunt A, Harrington D, Robinson S. (2014). Vitamin B12 deficiency. BMJ, 349:g5226. doi:10.1136/bmj.g5226 A practical clinical review.

8. Preclinical and Laboratory Findings

Animal and cell studies generate hypotheses. They should not be read as evidence of benefit in people.

In this edition, preclinical evidence is represented chiefly by the laboratory component of Kang 2015 and the biochemical work summarized in Sanders 2008 and Banerjee and Ragsdale 2003. A broader preclinical section (for example, B12 and nerve myelination in animal models) would require sources that were not verified for this edition and has therefore been left out rather than risk inaccurate citations. Findings in this category are preliminary and not established clinical benefits.

9. Study Summary Table

"Verify" means the detail was not confirmed for this edition. Doses are from the source where reliably known.

Year	First author	Design	Population	B12 form and dose	Duration	Key finding
2005	Vidal-Alaball	Cochrane systematic review	People with B12 deficiency (few small trials)	Oral vs intramuscular; verify	Short	Oral high-dose comparable to injection for serum levels
2018	Wang	Cochrane update	People with B12 deficiency	Oral vs intramuscular; verify	Short	Similar conclusion; low certainty for clinical outcomes
2010	Clarke	Meta-analysis of 8 RCTs	37,485 participants	B vitamin combinations	Varied	No significant effect on vascular events, cancer or mortality
1998	Kuzminski	RCT	People with cobalamin deficiency (small)	Oral vs intramuscular; verify	Short	Comparable response
2005	Eussen	Dose-finding RCT	Older adults with mild deficiency	Oral cyanocobalamin, several doses; verify	About 12 weeks	Dose-response in biomarkers
2010	de Jager	RCT	Type 2 diabetes on insulin	Metformin vs placebo (not B12 dosing)	Several years	Lower B12, higher deficiency risk with metformin
2010	Smith (VITACOG)	RCT	Older adults with MCI	Folic acid, B12, B6 combination	2 years	Slower brain atrophy, especially with high homocysteine
2006	Lonn (HOPE-2)	RCT	Over 5,000 with vascular disease or diabetes	Folic acid, B6, B12 combination	Several years	No reduction in main composite outcome
2013	Lam	Case-control	Large health-system cohort	Acid suppressants (exposure)	Varied	Association with B12 deficiency
2016	Aroda	Cohort analysis	DPP/DPPOS participants	Metformin (exposure)	Long-term	Association with low B12
2013	Arendt	Population cohort	Danish adults	Plasma B12 (marker)	Follow-up	High B12 a marker for cancer risk
2015	Kang	Small human and laboratory study	Healthy volunteers (small)	B12 supplementation; verify	Short	Altered skin bacterial gene expression

10. Links and Verification Status

• Official sources: NIH Office of Dietary Supplements fact sheet: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
• DOI links: To open any DOI listed above, use https://doi.org/ followed by the DOI string, or search the article title on PubMed (https://pubmed.ncbi.nlm.nih.gov/).
• Verification status: These citations come from well-established published work and were written from recall without live database access in this session. Every author list, DOI, finding and sample size must be checked against PubMed or the publisher before publication. Entries marked "verify" carry higher uncertainty. No reference has been invented knowingly, but a reviewer should confirm each one.

11. Research Gaps

• Few long-term randomized trials examine clinical (not just biochemical) outcomes of B12 supplementation.
• Evidence is limited in pregnancy, infancy, adolescence and across diverse ethnic groups.
• Trials often use combinations of B vitamins, which makes the effect of B12 alone hard to isolate.
• The size of drug-related B12 depletion for individual patients, and whether routine monitoring improves outcomes, remain unclear.
• Assay differences and biomarker thresholds vary, which complicates comparison across studies.
• Funding sources and conflicts of interest should be systematically reviewed in future editions.